The European Parliament has adopted its proposal to revamp the EU Pharmaceutical Legislation, which includes a Directive on the Union code regarding medicinal products for human use, and repealing Directive 2001/83/EC and Directive 2009/35/EC and a Regulation which repeals and replaces Regulation (EC) No 726/2004, the Regulation (EC) No 141/2000 (Orphan Regulation) and repeals and incorporates relevant parts of Regulation (EC) No 1901/2006 (Paediatric Regulation) to foster innovation and increase supply, accessibility, and affordability of medicines. This is the first major revision of the EU Pharmaceutical Legislation in over 20 years. MEPs want to introduce a minimum regulatory data protection period of seven and a half years, plus two years of market protection, following a marketing authorisation. MEPs also want to introduce market entry rewards and milestone payment reward schemes, to boost research and the development of novel antimicrobials, to combat antimicrobial resistance (AMR). They support the introduction of a 'transferable data exclusivity voucher' for priority antimicrobials, providing for a maximum of 12 additional months of data protection for an authorised product.